Browse Articles
Discover research articles across all indexed journals
Evaluation of systemic therapy and surgical consolidation in patients with node positive upper tract urothelial carcinoma.
816 Background: The recommended treatment for high-grade upper tract urothelial carcinoma (UTUC) includes radical nephroureterectomy with regional lymph node dissection for clinically organ-confined disease. The timing of peri-operative systemic therapy is multifactorial, with extrapolation of data from muscle-invasive bladder cancer in the neoadjuvant setting, and level 1 data for UTUC in the adjuvant setting. The timing of peri-operative systemic therapy and need for surgical consolidation in the clinically node positive setting is even more unclear. The goal of this study is to compare survival in cN+ patients managed with neoadjuvant, adjuvant, and systemic therapy alone approaches. Methods: Patients with cT0-4 N1-3 M0 UTUC who received chemotherapy with or without nephroureterectomy (NU) between 2018 and 2021 in the National Cancer Database (NCDB) were included. Patients were stratified into three treatment groups: chemotherapy only (CO), neoadjuvant chemotherapy followed by nephroureterectomy (NAC-NU), and nephroureterectomy followed by adjuvant chemotherapy (NU-AC). OS was analyzed using Kaplan-Meier analysis and log rank tests. Cox proportional hazard models were employed to adjust for potential confounders. Results: A total of 1193 patients were included (CO, NAC-NU, and NU-AC treatment groups consisted of 495, 287, and 411 patients, respectively). Patients in the CO group were older (P<0.001), more commonly males (P<0.001) compared with NAC-NU and NU-AC cohorts. There was no significant difference in Charlson comorbidity index between the three groups. The pathologic complete response rate (ypT0N0) in the NAC-NU was 6.5%. Patients managed with NAC-NU exhibited the most favorable OS compared to NU-AC and CO (P<0.0001), with 3-year OS 65.4% (95% CI 58.4%-73.3%), 53.5% (47.9%-59.6%), and 20.8% (15.7%-27.6%) in these groups, respectively. On multivariate analysis controlling for age, sex, and clinical stage using NAC-NU as a referent, NU-AC and CO exhibited inferior OS (HR 1.48, 95% CI 1.06-2.06, P=0.021 and HR 2.92, 2.14-4.00, P<0.001, respectively). Conclusions: The use of neoadjuvant chemotherapy followed by nephroureterectomy provides optimal survival outcomes in patients with cN+ high-grade UTUC. These data suggest that, when feasible, surgical consolidation is an important treatment component in patients with cN+ disease, likely owing to low rates of pathologic complete response. Estimated overall survival at 1- and 3-year endpoints. Treatment Sample Size 1 Year Survival (95% CI) 3 Year Survival (95% CI) Chemo Alone 348 57.6% (52.5% - 63.2%) 20.8% (15.7% - 27.6%) Chemo before Surgery 202 80.8% (75.4% - 86.6%) 65.4% (58.4% - 73.3%) Surgery before Chemo 329 72.8% (68.1% - 77.8%) 53.5% (47.9% - 59.6
Designing the weak Fermi pinning and p-type Ohmic contacts to monolayer halide perovskite Cs3Bi2I9
The contact between two-dimensional (2D) perovskite and metal electrodes is often plagued by strong Fermi-level pinning (FLP) effects, which limit the electronic performance of devices. By utilizing van der Waals design strategies, the contact performance between Cs3Bi2I9 and 1T/H-XA2 (X = V, Nb, Ta; A = S, Se) was investigated. P-type Schottky contacts are obtained in all 1T/H-XA2 contacts to Cs3Bi2I9, and the contacts can be engineered from Schottky to Ohmic contacts via external electric fields. Furthermore, a large pinning factor to suppress the FLP effects was observed to approach the Schottky–Mott limit, and the origin is elucidated. In addition, the transport properties of various 2D metals contacts to Cs3Bi2I9 were calculated and screened out. Finally, Curie temperature (Tc) of magnetic systems were calculated using the Monte Carlo method, and the Tc of 1H-VS2/Cs3Bi2I9 significantly enhances largely to surpass room temperature, thereby expanding the application field of spintronic devices. This study provides potential guidance for the design of efficient 2D Cs3Bi2I9-based nanodevices as well as high-temperature spintronic devices.
Breastfeeding self-efficacy status and associated factors among postpartum mothers at Hadiya Zone public hospitals, Southern Ethiopia
Background Breastfeeding is a crucial health-promoting behavior that has several positive effects on the health of both mothers and newborns. Breastfeeding self-efficacy (BFSE) status is an important factor that is positively related to breastfeeding, as it influences a woman’s decision to breastfeed or not. Therefore, the objective of this study is to assess the BFSE status and its associated factors among postpartum mothers at public hospitals in the Hadiya Zone. Method A cross-sectional study design was conducted from August 1–30, 2022, at public hospitals in the Hadiya Zone, southern Ethiopia. Data were collected from 416 participants using a pretested, structured questionnaire. Study participants were selected using a systematic random sampling technique from four public hospitals. The data were entered into Epi Data version 3.1 and analyzed using the SPSS version 24. Bivariable analysis was conducted initially, and variables with p values ≤ 0.25 were entered into multivariable logistic regression. Statistical significance was declared at a p value ≤ 0.05. Results The results of this study showed that 48% had a high level of BFSE. On multivariable logistic regression analysis, the variables age ≥ 35 years old [AOR = 3.596; 95% CI (1.564, 8.26)], age 20 to 34 [AOR = 2.352; 95% CI (1.2275, 4.506)], spontaneous vaginal delivery [AOR = 2.755; 95% CI (1.636, 5.566)], breastfeeding experience [AOR =1.845; 95% CI (1.028, 3.3)], more than secondary educational status [AOR = 6.856; 95% CI (2.670–17.603)], and intended pregnancy [AOR = 4.156; 95% CI (2.239, 7.714)] were significantly associated with high breastfeeding self-efficacy status. Conclusion The study findings suggest that mothers attending postpartum care at Hadiya Zone Hospital have a low status of breastfeeding self-efficacy. Therefore, efforts should be made to enhance mothers’ breastfeeding self-efficacy status before they are discharged from the hospital.
An automatic control system based on machine vision and deep learning for car windscreen clean
Understanding metastatic squamous cell carcinoma patients receiving pelvic exenteration vs radical cystectomy: A nationwide context.
681 Background: Squamous Cell Carcinoma (SCC) is a rare subtype of bladder cancers, consisting of 2-5% of all bladder cancers. SCC is associated with chronic bladder inflammation often due to catheters, kidney stones, and bladder outlet obstruction. While gold standard treatment for SCC is radical cystectomy (RC), many patients receive more extensive surgery such as pelvic exenteration (PE). PE involves removing all organs from a person’s pelvic cavity whereas RC involves removing the bladder and nearby tissue. This study will examine the characteristics of metastatic SCC patients receiving PE vs RC to better understand why some patients may not receive RC. Methods: The National Cancer Database (NCDB) was used to identify patients diagnosed with bladder squamous cell carcinoma from 2004 to 2020 using the histology codes 8050, 8070-8076, 8084 and NCDB analytic stage code IV as assigned by the Commission on Cancer Accreditation program. Kaplan-Meier, ANOVA Chi-Square, and Cox Proportional Hazards tests were performed. Data was analyzed using SPSS version 27 and statistical significance was set at α = 0.05. Results: Of the 561 patients in the sample, 211 (37.6%) received PE and 350 (62.4%) received RC. Patients receiving PE survived 32.8 months and patients receiving RC survived 35.8 months (p>0.05). Patients receiving PE were more likely to receive adjuvant radiation or chemoradiation, have no residual tumor or microscopic residual tumor after surgery, receive care from an academic facility, and to have lymph vascular invasion (p<0.05). These patients were also more likely to present at a younger age (62.86 vs 65.37 years) yet interestingly were more likely to have fewer regional lymph nodes positive (9.27 vs 14.90) (p<0.05). There were no significant differences between income level, race, the number of comorbid conditions (Charlson-Deyo Score), insurance status, tumor size, or time to surgery (p>0.05) between the two groups. Conclusions: 37.6% of patients in this sample received PE over RC, the gold standard. PE patients had disease that more greatly invaded the lymphatics and had better surgical margins, yet PE offered no significant survival benefit. More research is needed to better understand why some patients receive more extensive surgical intervention.
Efficacy, Toxicity, and Cosmesis of Partial Breast Irradiation: Honing in on Dose and Patient Selection
Survival outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium-177-PSMA-617 (Lu) based on line of therapy.
82 Background: Lu is a prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical that delivers beta radiation to PSMA-positive cells. It is approved for pts with mCRPC who had prior progression on an androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy. However, there are limited real-world data on the efficacy of Lu based on the line of therapy. Herein, we aimed to assess the survival outcomes of pts with mCRPC receiving Lu in a real-world setting. Methods: This retrospective study utilized the nationwide Flatiron Health electronic health record (EHR) derived de-identified database. Eligibility: pts diagnosed with mCRPC who received Lu for the first time. Survival was calculated from the date pts received their first treatment with Lu. Time to next treatment (TTNT) and overall survival (OS) were summarized using Kaplan Meier survival estimates and its 95% confidence intervals (CI). Results: Of the overall cohort of 24,105 pts with metastatic prostate cancer in the dataset, 303 diagnosed between 1/1/2013 and 7/11/2023 received treatment with Lu. The median age of these pts was 75 years (IQR 69 – 80). The majority were White non-Hispanic (69%), treated in a community practice (82%), covered by a commercial health plan (86%), and received Lu in the third line or later (91.4%). For pts treated with Lu, the median TTNT was 8.5 months (95% CI, 7.3 – 9.8), and the median OS was 12 months (95% CI, 11 – 15). Median TTNT and OS by line of therapy are summarized (Table). Conclusions: Lu retains clinical activity in pts with mCRPC regardless of line of therapy. These data may aid with patient counseling, prognostication, and selection of therapy in the clinic. Median TTNT and OS by line of therapy in pts with mCRPC receiving Lu. Line of therapy Number of pts, n (%) Median TTNT (mo) (95% CI) Median OS (mo) (95% CI) 2 26 (8.6) 8.5 (5.6, -) 12 (8.5, -) 3 77 (25.4) 8.0 (6.4, 11) 17 (8.9, -) 4 82 (27) 8.2 (6, 10) 10 (7.2, 22) 5 64 (21) 9.8 (6, 13) 13 (11, -) 6 28 (9.2) 9 (5.7, -) 13 (12, -) 7 17 (5.6) 10 (7.3, -) 10 (7.3, -) 8 6 (2) 7 (3.7, -) (3.7, -) 9 2 (0.7) 7.3 (3, -) 10 (8.6, -) 14 1 (0.3) 8.6 (-, -) 14 (-, -)
Additivity and the efficacy of immune checkpoint blockade-based combination regimens in urothelial cancer.
779 Background: Immune checkpoint blockade (ICB)-based combination regimens have transformed the treatment landscape of advanced solid tumors including urothelial cancer. Understanding whether such combinations are synergistic, additive, or less than additive is crucial for (a) refining combination therapy in urothelial cancer, (b) dissecting the role of concurrent versus sequential treatment, and (c) identifying which cytotoxic agents combine most favorably with ICB. Here we analyzed phase III trials in advanced urothelial cancer to determine if the efficacy of combination therapies were predictable by additivity or exhibited non-additive effects. Methods: We analyzed progression-free survival (PFS) from phase III trials of ICB-containing regimens for advanced urothelial cancer (Table). PFS distributions of constituent drugs were used to calculate the predicted PFS of combination therapy under the null hypothesis of additive PFS times (Hwangbo et al, Nature Cancer, 2023). For KEYNOTE-361 and IMvigor130, which allowed investigator’s choice of cisplatin or carboplatin, separate predictions were made for cisplatin- and carboplatin-treated cohorts. The Cox Proportional Hazards model tested whether observed PFS significantly differed from additivity. Results: PFS of combination therapies in EV-302, CheckMate901, and DANUBE were statistically indistinguishable from additivity (Table). Trials using choice of cisplatin or carboplatin (KEYNOTE-361, IMvigor130) showed that ICB with cisplatin produced additive PFS, but ICB with carboplatin was significantly antagonistic (inferior to additive PFS; P = 0.00004). Conclusions: Recently approved regimens enfortumab vedotin + pembrolizumab, and nivolumab + gemcitabine-cisplatin, were as effective as predicted by additivity, demonstrating that combining individually effective agents without synergy can make effective regimens. In advanced urothelial cancer, PD-1 or PD-L1 inhibitors are antagonistic with carboplatin, but confer additive PFS benefits with cisplatin. Modeling the PFS of combination regimens from single agent data could have predicted the success of most contemporary phase III trials in advanced urothelial cancer. Trial Combination Predicted HR for PFS (95% CI) Observed HR for PFS (95% CI) P value EV-302 Enfortumab vedotin + Pembrolizumab 0.49 (0.44 - 0.55) 0.45 (0.38 - 0.54) 0.93 CheckMate901 Nivolumab + Gemcitabine-Cisplatin 0.69 (0.60 - 0.79) 0.72 (0.59 - 0.88) 0.78 DANUBE Durvalumab + Tremelimumab 0.87 (0.78 - 0.98) 0.88 (0.75 - 1.03) 0.92 KEYNOTE-361 Pembrolizumab + Chemotherapy 0.67 (0.59 - 0.77) 0.78 (0.65 - 0.93) 0.02 IMvigor130 Atezolizumab + Chemotherapy 0.61 (0.55 - 0.68) 0.82 (0.70 - 0.96) 0.0006 Pooled ICB + Gemcitabine-Cisplatin 0.65 (0.56 - 0.74) 0.71 (0.58 - 0.86) 0.78 Pooled ICB + Gemcitabine-Carboplatin 0.63 (0.57 - 0.70) 0.84 (0.73 - 0.97) 0.00004
Erratum: “Epitaxial (AlxGa1−x−yIny)2O3 alloys lattice matched to monoclinic Ga2O3 substrates” [Appl. Phys. Lett. <b>125</b> , 172106 (2024)]
Assessment of potential dominant factors for brownfield landscape regeneration: A case study in Xi’an, China
Rapid global urbanization has made brownfield reuse a vital issue for sustainable urban development. However, the regeneration of brownfield landscapes is a complex and lengthy process that requires a combination of factors to be considered. Their landscape regeneration must be planned and prioritized to utilize brownfield sites and achieve positive social benefits. Therefore, an urgent need must be established to establish an assessment framework and system for various types of brownfield landscape regeneration dominant factors to find different brownfield landscape regeneration dominant factors. This research developed an assessment model using the Analytic Hierarchy Process (AHP), covering five brownfield types: industrial, mining, military, transportation, and landfill in Xi’an, China. The potential assessment factors in three levels were analyzed for weighting to explore the dominant factors for the potential regeneration of brownfield landscapes in Xi’an. The results showed that, firstly, among the five first-level assessment factors, the physicality factor was the most important. Secondly, among the 16 second-level factors, the spatial and physical features of the visual landscape were the most critical. Finally, among the 40 three-level factors, spatial features were the primary factor. Therefore, the purpose of this research is to provide a specific assessment system and data analysis methods and ideas for the dominant factors of urban brownfield landscape regeneration in China and other regions based on the assessment framework with strong adaptability proposed by the AHP method, which can be flexibly adapted in the different areas and countries, to realize the sustainable development of cities in various regions.
Antiviral defence arsenal across members of the Bacillus cereus group
Abstract Bacteria co-evolve with bacteriophages to overcome each other’s defence arsenal. Bacillus cereus group gathers bacteria of medical and agricultural importance, including foodborne pathogens. So far, few studies have portrayed a complete defence arsenal of microorganisms, and the role of antiviral systems in the Bacillus cereus group has been overlooked. Here, we investigate the repertoire of defence systems in 6354 B. cereus group’s genomic assemblies, using bioinformatics tools DefenseFinder and PADLOC. Our analyses provide an overview of the diversity and abundance of defence systems in this group, with 83,738 systems distributed by 2 to 33 within each assembly. Comparing PADLOC and DefenseFinder predictions showed that the most prevalent strategy is Restriction-Modification, but many abortive infection systems also intervene in the group’s defence, such as Septu, Gabija and Lamassu. Most defences were encoded on both plasmids and the chromosome, though some tend to have a preferential genomic location. We also studied the defence systems associations within the genomic assemblies. Overall, our results establish a baseline picturing the rich and complex antiviral arsenal encoded by B. cereus group’s species and provide clues for studying co-existing strategies displayed by these bacteria to subvert phages and other MGEs invasions.
Evaluating associations between genomic classifier and digital pathology–based multi-modal AI biomarkers in oligometastatic castration-sensitive prostate cancer.
231 Background: Prostate cancer is a heterogeneous disease ranging from indolent localized to metastatic castration-resistance. Efforts to generate prognostic and predictive biomarkers to understand disease trajectory beyond clinical variables alone include the Decipher Prostate Genomic Classifier (GC) and Artera Multimodal AI (MMAI). Both are validated prognostic biomarkers within localized prostate cancer and are currently being evaluated in the metastatic setting. It is unknown if these biomarkers are reporting on similar biology through different means (gene expression vs digital pathology) or if they are complementary and provide orthogonal insights. Herein, we aim to correlate GC and MMAI scores in patients with metastatic prostate cancer. Methods: We conducted a retrospective review of patients with oligometastatic castration-sensitive prostate cancer (omCSPC) with available transcriptome and digital H&E images from prostate biopsy tissue. GC scores were calculated from RNA sequencing data using the same coefficients but scores were re-scaled to a reference cohort from GRID registry while missing features were imputed as 0. Following digitization of H&E slides, an AI-detected, 128 image feature vector (IFV) was generated per patient which was subsequently combined with Gleason score, PSA, and T stage for final MMAI scoring (Artera, Inc). The primary endpoint was to assess correlations between these biomarkers as continuous variables with linear regression. Given the MMAI score is composed of both AI-detected digital pathology features and clinical features, we evaluated any associations between the GC and AI-detected image features. Uniform Manifold Approximation and Projection (UMAP) was performed on the 128 IFV to generate digital pathology clusters which were then associated with GC both as a continuous and categorical variable using ANOVA and chi-square test, respectively. Results: 85 patients (Metachronous n=74; Synchronous n=11) were included in the analysis. The median GC and MMAI scores were 0.60 and 0.52, respectively. Linear regression identified a very weak positive association between scores (R 2 =0.08, 95%CI 0.00-0.20). UMAP identified 4 digital pathology clusters. No cluster was found to be enriched with higher GC scores with median scores of 0.64, 0.67, 0.58, and 0.5 for clusters 1-4 respectively (p=0.138). Additionally, no cluster was enriched with either low (GC <.45, p=0.87), intermediate (GC ≥ 0.45-<0.6, p=0.73), or high (GC≥0.6, p=0.12) GC risk groups. Conclusions: We demonstrate for the first time that Decipher GC and Artera MMAI scores do not strongly correlate in a population of patients with omCSPC. This suggests these biomarkers may be complementary, identifying independently prognostic disease biology. Further work validating these findings is warranted.
Can magnetic resonance imaging safely replace a confirmatory biopsy in patients on active surveillance for prostate cancer?
331 Background: Active surveillance (AS) is recognized as the preferred management for patients with low-risk prostate cancer, and many with favorable intermediate risk tumors as well. AS has been increasing in utilization both within the Veterans Affairs (VA) Healthcare System and nationally in the U.S. However, the limited data evaluating the quality of AS protocols suggests wide variability. One area of controversy is whether magnetic resonance imaging (MRI) can replace prostate biopsy to guide decisions about whether to remain on AS. We aimed to quantify the performance characteristics of MRI as a potential replacement for biopsy in a large, diverse, national VA cohort. Methods: The study cohort consists of veterans diagnosed with Gleason grade group (GG) 1 or 2 prostate cancer at their diagnostic biopsy undergoing AS. The cohort is further limited to patients that underwent at least one post-diagnosis (confirmatory) biopsy and had at least one MRI with an assigned Prostate Imaging-Reporting and Data System (PI-RADS) score completed within 180 days prior to their confirmatory biopsy (CBx) and/or any subsequent surveillance biopsy (SBx). MRI was evaluated as negative (PI-RADS v2.1 score of 1-2) or positive (PI-RADS score of 3-5) in its ability to predict GG≥2 prostate cancer on post-diagnosis biopsy, vs. either negative or GG1. We focused on the negative predictive value (NPV), given the key clinical question whether MRI can safely replace biopsy, and stratified results by PSAD (< 0.15 ng/mL and >= 0.15 ng/mL) and GG groups (GG1 vs GG2) at diagnosis. Results: We identified 1,662 cases with eligible confirmatory biopsies and 796 cases with eligible surveillance biopsies among 2,188 patients. Biopsies were from patients with a median age of 67 with 80% having GG1 cancer at their diagnostic biopsy and the remaining 20% at GG2. The negative predictive value (NPV) was 74% for all confirmatory biopsies and 75% for subsequent surveillance biopsies. Performance was worse in some contexts: for example, among patients with GG2 at diagnosis, NPV was only 38% at the confirmatory biopsy and 60% at subsequent surveillance biopsies. On the other hand, for those with PSAD less than 0.15 ng/mL, NPV at the surveillance biopsy was 82% (Table). Conclusions: Negative MRI—as defined by PI-RADS 1-2—does not consistently rule out the presence of GG≥2 prostate cancer and therefore cannot safely replace confirmatory biopsy. In some contexts (e.g., subsequent surveillance biopsy for patients with low PSAD) MRI may be an adequate surrogate. Group Type of Biopsy Count NPV PPV Sensitivity Specificity Overall CBx 1,662 0.74 0.53 0.96 0.13 Overall SBx 796 0.75 0.52 0.97 0.10 GG1 CBx 1,317 0.79 0.49 0.96 0.14 GG1 SBx 672 0.77 0.48 0.96 0.10 GG2 CBx 345 0.38 0.69 0.96 0.06 GG2 SBx 124 0.60 0.72 0.98 0.08 Low PSAD CBx 755 0.78 0.60 0.98 0.10 Low PSAD SBx 382 0.60 0.61 0.96 0.08 High PSAD CBx 693 0.75 0.43 0.93 0.15 High PSAD SBx 309 0.82 0.42 0.96 0.12
Ethnic disparities in clinical trials for FDA-approved drugs in prostate cancer: A post–COVID-19 era analysis (2020-2024).
25 Background: It is known that ethnic and racial inequality in participation in oncology clinical trial is a contemporary problem. Efforts have been made by NCI and FDA to address cancer disparities as per new policies placed in 2017. Despite these efforts, there are still disparities in cancer treatment and clinical trial participation. There is paucity of data in participation of minorities in the post COVID-19 era of the FDA approved agents in Prostate Cancer. Methods: From 2020-2024, a total of 4,744 patients participated in the seven clinical trials (MAGNITUDE, TALAPRO-2, VISION, PROPEL, ARASENS, HERO, PROfound and TRITON3) that led to FDA approval of new agents or indications to treat patients with prostate cancer. All clinical trials were industry-sponsored. We assessed and tabulated the reporting of racial demographics within these trials employing chi-square statistics and machine learning algorithms to compare participation rates among White, Black, Asian and Hispanic patients against SEER data on prostate cancer incidence. Results: Among the eight trials, five (ARASENS, MAGNITUDE, PROPEL, TALAPRO, TRITON-3) reported racial data in White, Asian and Black participants, but only one reported data on Hispanics (MAGNITUDE). Our analysis revealed that in the five trials providing racial data, 68% were White indicating statistically significant overrepresentation (p<0.001), Black participation was only 3% signifying statistically significant underrepresentation with (p<0.0001). In the only trial with data in Hispanics, there was a 12.1% participation of Hispanics with no significant disparity observed (p=1). Conclusions: Lack of representation of minorities persist in post COVID area FDA approved drugs clinical trials in prostate cancer. Lack of a more comprehensive data in race have also been seen in recent trials. Further implementation of policies for better data capture and standardization in the nomenclature of ethnicity should be pursued. Additionally, in international collaboration trials, a separate data on US participants utilizing NCI SEER data ethnicity nomenclature should be considered.
Development of an ex-vivo platform to model immunotherapy in kidney cancer.
592 Background: The treatment landscape for metastatic clear cell renal cell carcinoma (mccRCC) has evolved, with immune checkpoint inhibitor (ICIs) combinations contributing to improved survival. However, many patients remain unresponsive, highlighting the need for alternative strategies. While preclinical models have been instrumental in drug development, their translation to human applications often encounters challenges related to reproducibility. This emphasizes the urgent requirement for accurate, immunocompetent models of ccRCC that reflect human disease, identify effective immunotherapy regimens, and support reliable drug development. This study presents the development and characterization of a precision cut tissue slices (PCTS) model for primary ccRCC, capturing patient-specific heterogeneity. Methods: Twelve patients undergoing nephrectomy for primary ccRCC were consented. PCTS were obtained and co-cultured with autologous peripheral blood mononuclear cells (PBMCs) (5x10^5 co-cultured with one PCTS) and treated for six days. Treatment groups included: i) cabozantinib (cabo) alone, ii) cabo with cemiplimab (cemi, a PD-1 inhibitor), iii) cemi with fianlimab (fin, a LAG-3 inhibitor), and iv) the triplet regimen of cabo, cemi, and fin. The co-cultured PCTS were analyzed using H&E staining and a Live-Dead stain to assess cell viability. Following co-culture, PBMCs were imaged and cytospun for histological analysis and characterized using multiplex immunofluorescence (MxIF). Results: Viability assessment of co-cultured PCTS indicated a significantly higher proportion of dead cells in the triplet-treated group (cabo+cemi+fin) compared with either doublet strategy. Additionally, the number of viable PBMCs, assessed six days post-co-culture, was also highest in the triplet group. Ongoing MxIF analysis aims to characterize the PBMCs further. Conclusions: This study characterizes an organotypic, patient-derived model based on the culture of tumor slices from primary renal cancers, where we have optimized for extended viability of PCTS in ex vivo culture. The drug treatment experiments conducted on the slices demonstrate the potential of PCTS as a preclinical tool for screening effective therapies for primary ccRCC, including immunotherapeutic approaches, which has been challenging in previous animal models. Our findings suggest that the triplet regimen (cabo+cemi+fin) may offer greater efficacy compared to the cabo+cemi or cemi+fin. Based on these results, an early-phase clinical trial to investigate the triplet in ccRCC patients is under development.
High-performance GaSb-based interband cascade lasers with a top hybrid cladding
We report high-performance GaSb-based interband cascade lasers (ICLs) with a top hybrid cladding and operating around 3.5 μm at room temperature. Unlike the conventional superlattice (SL) claddings in GaSb-based ICLs, the top cladding of the present ICLs consisted of an n-SL, followed by an n+-InAs0.91Sb0.09 layer, while their bottom claddings entirely consisted of an n-SL. This “asymmetric” waveguide design is potentially advantageous, since it improves the active-core optical confinement factor, as well as the overall thermal conductance, especially for epitaxial-side-down mounted devices. When operated in pulsed mode, the broad-area ICL featured a characteristic temperature of 57 K and a threshold current density as low as 95 A/cm2 at 25 °C, which is the lowest ever reported for an ICL operating at a similar temperature. The narrow-ridge device processed from the same wafer, operated in continuous-wave (CW) mode up to a temperature as high as 100 °C, with a CW threshold current density of only 150 A/cm2 at 20 °C, although the current leakage was appreciable at the sidewalls.
Quantitative nylon monomerization by the combination of chemical pretreatment and enzymatic hydrolysis using nylon hydrolases
Nylons, derived from fossil fuels, are widely used for their toughness and flexibility, but they pose environmental concerns due to their low biodegradability. This study explored an efficient method for the monomerization of polymeric nylons, specifically nylon-6 and nylon-6,6, through a combination of chemical pretreatment and enzymatic hydrolysis using two kinds of nylon hydrolases, NylB and NylC (Nyl series enzymes). To break down the strong intermolecular hydrogen bonding between polymer chains of nylon, two pretreatment methods were investigated: homogeneous dispersion and soluble oligomerization induced by acid treatment. Homogeneous dispersion enhances water solubility, while soluble oligomerization reduces the molecular weight. These pretreatments significantly increased the enzyme sensitivity of the nylons, resulting in nearly complete conversion into monomers by Nyl series. Finally the convincing monomerization toward market products such as used fishing nets was also achieved. This study highlights the potential of this methodology for chemical recycling, offering a promising solution for reducing environmental impacts and achieving a circular economy for nylon products.
Association between breakfast nutrient density, subsequent meal quality, and overall diet quality in Iranian adults: a cross-sectional study
Lenvatinib's efficacy in heavily pre-treated metastatic renal cell carcinoma: Insights from a European multicenter study.
510 Background: Lenvatinib-based therapy has shown efficacy in the frontline treatment of metastatic renal cell carcinoma (mRCC). However, there is uncertainty about the role of Lenvatinib (LEN) in subsequent lines of treatment, particularly after immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI). This study aimed to describe the real-world clinical outcomes of patients (pts) with mRCC treated with LEN-based therapies beyond first-line treatment. Methods: Retrospective multicenter study including all pts with mRCC treated with LEN-based therapies beyond first-line at seven European centers from October 2020 to August 2024. Data on patient characteristics, treatments, and outcomes were collected. The primary endpoints were objective response rate (ORR) and progression-free survival (PFS). Secondary endpoints included disease control rate (DCR), overall survival (OS), and safety. This study was approved by a centralized institutional review board (Gustave Roussy). Results: A total of 115 pts were included, 80% males, with a median age of 60.0 years. Of them, 80.9% had clear-cell subtype. Lenvatinib was mainly used after a median of 3 previous lines of treatment (range 2-8), either alone (41.7%) or in combination with everolimus (35.7%), pembrolizumab (PEM) (20.0%), or investigational agents (2.6%). Most of the pts had previously received ICI (88.7%) or TKI (96.5%), including cabozantinib (89.6%). The ORR was 28.2% and DCR was 65.5%. With a median follow-up time of 13.5 months (mo), the median PFS was 6.0 mo (95% CI 4.3-8.4 mo). Previous Cabozantinib (HR 4.3, p=0.02), bone metastases (HR 2.1, p=0.002) and the intermediate (HR 3.4, p=0.009) or poor IMDC risk (HR 7.7, p<0.001) significantly impacted PFS in the multivariate analysis. Median OS was 10.1 mo (95% CI 6.9-12.4 mo). Multivariate Cox models identified poor IMDC risk (HR 7.4, p<0.001) and bone metastases (HR 2.3, p=0.002) as negative independent prognostic factors for OS. On the contrary, LEN-PEM treatment (HR 0.3, p=0.017) had a positive impact on OS. Up to 38.3% of the pts started LEN with a dose adjustment (<18mg per day). On treatment, dose modifications were required in 33.9% of pts, with 9.6% discontinuing due to toxicities. Conclusions: In our cohort, LEN demonstrated meaningful clinical activity in heavily pretreated mRCC pts. The safety profile was manageable. These findings provide evidence to support its utilization in pretreated pts with mRCC.
Recurrence and its association with overall survival (OS) in muscle-invasive bladder cancer (MIBC) patients undergoing radical cystectomy (RC): A real-world analysis.
705 Background: MIBC is a heterogenous disease, encompassing T2-T4 tumors with or without nodal disease (T1-T4aN1). A primary treatment modality for MIBC is RC, often supplemented by neoadjuvant (NAD) and/or adjuvant (AD) therapies for select patients. Despite RC, patients with MIBC have a high risk of disease recurrence and progression. This study aimed to describe the real-world, contemporary impact of disease stage at diagnosis and treatment received on cancer recurrence and OS and examine the association between recurrence and OS. Methods: This retrospective study quantified recurrence and OS and the association of recurrence with OS among patients with MIBC (T2-T4aN0M0/T1-T4aN1M0) who had RC. Adult MIBC patients undergoing RC between January 1, 2008 and July 1, 2023 were identified using the U.S. ConcertAI Patient360 Bladder Cancer electronic medical record database in a predominantly community-based oncology setting. Index date was defined as the date of RC. Recurrence was defined as the first recorded disease progression >7 days after RC. Proportions of recurrence and OS were analyzed using Kaplan-Meier analysis overall and stratified by disease stage and treatment received. Association of recurrence with OS was assessed using Cox regression adjusted for patient characteristics. Results: 783 RC-treated MIBC patients met study inclusion criteria (median age 68 years; male 79%; White 88%; de novo MIBC 77%; urothelial histology 77%), with median follow up of 26 months (IQR: 11–48). At MIBC diagnosis, 73% were clinical stage T2N0, 21% were T3/4aN0, and 6% were T1-T4aN1. Almost half the patients (48%) underwent RC alone, while 46% received NAD+RC, 4% received RC+AD, and 3% received NAD+RC+AD. Over time, NAD use doubled from 30% (2011–2013) to 62% (2020–2022). Among patients who received NAD and had evaluable pathological staging (n=240), 26% achieved pathological complete response (pT0pN0). The overall 5-year recurrence rate was 45%, with variation by disease stage and treatment (Table). The 5-year OS was 48% overall and was significantly lower for patients with recurrence compared with those without (17% vs 69%, p<0.0001). Mortality was 4.4 times higher [95% CI: 3.5, 5.6] among those with recurrence compared to those without. Conclusions: MIBC patients undergoing RC had high recurrence rates, irrespective of disease stage at diagnosis or treatment modality received. Recurrence was associated with increased mortality rate. These findings underscore the substantial clinical burden for surgically treated MIBC patients and the need for more effective treatments that can delay or prevent recurrence and improve OS. Recurrence and OS by stage and treatment group. 5-Year Recurrence Rate % 5-Year OS Rate % Stage at MIBC Diagnosis T2N0 42 50 T3/T4aN0 52 47 T1-T4aN1 59 31 Treatment Group RC Alone 48 44 NAD+RC 39 56 RC+AD 67 29 NAD+RC+AD N/A 26